Zydus Lifesciences, Lupin sign licensing agreement to co-market Semaglutide Injection in India

17 Mar 2026 Evaluate

Zydus Lifesciences has entered into a Licensing and Supply Agreement with global pharma major, Lupin to expand access to innovative Semaglutide Injection (15 mg/3 ml) with patient-friendly reusable pen device in India. This partnership brings together the company’s strong product development capabilities and Lupin’s extensive reach in the Indian market, with the shared objective of bringing advanced therapies for metabolic disorders.

Under this agreement, Lupin will have semi-exclusive rights to co-market the company’s innovative Semaglutide Injection in the Indian market under the brand names Semanext and Lupin’s Livarise. The company will market the product under the brand names SEMAGLYN, MASHEMA and ALTERME. Lupin will pay the company upfront licensing fees and milestone payments on achieving pre-defined milestones.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

890.60 14.25 (1.63%)
20-Mar-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.20
Dr. Reddys Lab 1295.00
Cipla 1260.65
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×